Abstract: Both the A194T and a quadruple mutation CYEI (S106C, H126Y, D134E and L269I) in hepatitis B virus (HBV) polymerase reverse transcriptase domain (pol/RT) are suggested to be associated with treatment failure with tenofovir disoproxil fumarate (TDF).
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Abstract: A recent Korean report showed that two patients with viral breakthrough during treatment with TDF-containing regimens were found to carry five reverse transcriptase (rt) mutations ([rt]S106C[C], rtH126Y[Y], rtD134E[E], rtM204I/V, and rtL269I [I]), with the C, Y, E, and I mutations being associated with tenofovir resistance.
Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes.
PMID: 33562603
2021
International journal of molecular sciences
Introduction: Despite its high genetic barrier to resistance, we have previously reported that a novel quadruple mutation (CYEI; rtS106C (C), rtH126Y (Y), rtD134E (E), and rtL269I (I)) is associated with tenofovir resistance.
Method: Two clones (CYEI: rtS106C (C) + rtH126Y (Y) + rtD134E (E) + rtL269I (I) and CYELMVI: rtS106C (C) +
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
Method: For this analysis, we considered a total of 12 RAMs (S106C/G, D134E, R153W/Q, V173L, L180M, A181T/V, A194T, A200V, M204I/V, L217R, L229V/W and I269L).
Result: We considered the distribution of 12 RAMs (S106C/G, D134E, R153W/Q, V173L, L180M, A181T/V, A194T, PMID: 32765014
2020
Infection and drug resistance
Discussion: Furthermore, some variants were related to DR to entecavir and tenofovir disoproxil fumarate, such as rtI169T, rtl180M, rtM204I/V, rtH126Y and rtD134E, which have been previously reported, and were also found in the present study.
Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations.
PMID: 32994690
2020
World journal of gastroenterology
Introduction: In addition, rtS106C+rtH126Y+rtD134E+rtL269I quadruple mutations have recently been reported to confer TDF resistance.
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
Abstract: RESULTS: Five mutations (rtS106C [C], rtH126Y [Y], rtD134E [E], rtM204I/V, and rtL269I [I]) were commonly found in viral isolates from 2 patients.
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Introduction: The fourth category could be found before NA therapy, such as T38A, Y124H and D134E.
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
4Method:
Method: In this study, rtD134E/N/C was the most frequently encountered hot spot site among the six A-B inter-domain sites and was mutated in 12/79 patients (15.2%).
Method: Of note, the following four putative or pretreatment mutations found in treatment naive patients, rtD134E/N, rtN139D/E/H/K/Q, rtF221Y, and rtI224V, are also reported as associated with progression of severe liver diseases, such as HCC and cirrhosis (described below).
HBV mutation literature information.
PMID: 
2022
Biomedicines
Browser Board
Co-occurred Entities
Filtrator
ViMRT